Panacea Biotec Supreme Court Judgment (2026): Limitation and Section 202 CrPC in Drugs Act Prosecutions

Case Summary

• Case name: The State of Kerala & Anr. v M/s Panacea Biotec Ltd. & Anr.; also appeals involving M/s Veekay Surgicals Pvt. Ltd. (Criminal Appeals arising from SLP (Crl.) Nos. 4524/2023, 18999/2023, 8867/2023)

• Date of decision: 26 February 2026

• Bench: Honourable Justice Ahsanuddin Amanullah and Honourable Justice S.V.N. Bhatti

• Advocates appearing: Mr H. V. Hameed for the State; Mr Siddharth Luthra (senior counsel) for the Respondents in the primary appeals

• Statutes and rules considered: Drugs & Cosmetics Act, 1940 (Sections 17(b), 17(c), 18(a)(i), 27(d), 32, 34; Section 23(4)(i)); Drugs and Cosmetics Rules, 1945 (Rule 96); Code of Criminal Procedure, 1973 (Sections 200, 202, 468, 469, 473, 293)

• Principal legal issues: (1) Limitation for taking cognisance (Sections 468 to 469 read with Section 473 CrPC); (2) Territorial jurisdiction and mandatory enquiry under Section 202 CrPC when accused reside beyond the Magistrate’s jurisdiction; (3) Applicability of Section 32 of the Drugs Act (complaints by Inspectors or public servants); (4) Vicarious liability under Section 34 of the Drugs Act

• Key authorities cited: Cheminova India Ltd. v State of Punjab (2021); Birla Corporation Ltd. v Adventz Investments and Holdings Ltd. (2019)

Introduction

This judgment, delivered by Honourable Justice Ahsanuddin Amanullah (with Honourable Justice S.V.N. Bhatti concurring), resolves three connected criminal appeals arising out of High Court orders which had quashed complaints under the Drugs & Cosmetics Act on varied grounds. The Supreme Court’s unanimous ruling restores the prosecution insofar as the decisions under challenge concerned limitation and the need for enquiry under Section 202 CrPC, and remits certain factual questions to trial. The decision is of practical significance for prosecutors and defence practitioners in pharmaceutical regulatory enforcement, and for magistrates asked to balance procedural safeguards against the public interest in consumer protection offences.

Factual Background

The complaints originate from alleged mislabelling or misbranding and sale of sub standard drugs and medical devices. In the Panacea matter, the complaint began with a private informant (a purchasing medical officer) whose allegation that an outer carton described a pentavalent vaccine but inner vials bore tetravalent labels prompted departmental enquiries. The Drugs Inspector (a state official) thereafter initiated a prosecution in 2009. The High Court quashed the complaint against the manufacturers primarily on the ground that the Chief Judicial Magistrate had failed to conduct the statutory enquiry under Section 202 CrPC, despite the accused residing outside his territorial jurisdiction. Relatedly, the High Court entertained limitation objections. In the Veekay matter, a Government Analyst’s report found syringes not of standard quality; the High Court quashed proceedings for non compliance with Section 202 and for insufficient pleading of culpability under Section 34 of the Drugs Act.

Issues and Judicial Approach

At the heart of the appeals were two legal questions: (1) whether limitation ran against the prosecution; and (2) whether Section 202(1) CrPC compelled a magistrate to postpone process and conduct an enquiry in complaints instituted by a public servant (an Inspector). The Bench also examined whether allegations against directors under Section 34 of the Act were mere bald averments or adequate to proceed to trial.

Limitation Analysis

The Court adopts a purposive and pragmatic reading of Sections 468 to 469 and Section 473 CrPC. It emphasised that where the identity of the offender becomes known during departmental inquiry or investigation, Section 469(1)(c) governs the commencement of the limitation period. The Court held that the competent authority’s verification or investigation into the supplier chain was part of the investigative continuum; the three year limitation began to run only after the identity of the accused was established which, on the facts, was 18 April 2006. Because the formal complaint was presented within three years thereafter, the limitation bar did not arise.

Section 202 CrPC and Territorial Jurisdiction

The Court relied heavily on Cheminova to hold that complaints filed by public servants in discharge of official duty occupy a different plane. The interplay between Section 200 CrPC exemption from examination where complaint is by a public servant acting in discharge of official duties and Section 202(1) CrPC was resolved in favour of allowing magistrates discretion; when a complaint has been made by an Inspector in the official discharge of duty and is supported by departmental enquiries and admissible expert reports, the strict mechanics of Section 202 need not be mechanically applied so as to frustrate the public interest. In short, the presence of a statutory complainant (an Inspector) and the corroborative departmental material meant that the High Court erred in quashing the complaint solely for alleged non compliance with Section 202.

Directors’ Liability Under Section 34

The Court was cautious about prematurely deciding the question of directors’ liability under Section 34. It emphasised that whether a director was in charge of or responsible to the company are questions of fact for the trial court. The Supreme Court set aside the High Court’s conclusion that a bald averment would suffice to quash: rather, such factual questions are to be determined at trial by appropriate evidence.

Key Judicial Observations

The judgment contains practical dicta for magistrates and prosecutors: first, limitation must be computed with regard to the moment the identity of the offender becomes known as a result of inquiry; second, complaints initiated by Inspectors or other public servants in discharge of statutory functions attract a different regime, especially where there is corroborative material such as Government Analyst reports or seized invoices; third, courts should avoid short circuiting questions of corporate and officer liability that require evidence. As the Bench put it, the Code of Criminal Procedure itself provides for exemption from examination of such witnesses, when the complaint is filed by a public servant, a passage the Court borrowed and relied upon from Cheminova.

Where the complaint is made by an Inspector acting in discharge of official duty and is supported by departmental verification and analyst reports, the magistrate’s mechanical recourse to Section 202 should not defeat the public interest in prosecuting offences that affect consumers.

Practical Implications

Prosecutors should ensure a clear administrative paper trail when departmental complaints are lodged: dated inspection notes, seized invoices, analyst reports and statements are valuable to rebut jurisdictional and limitation objections at the threshold. Defence practitioners should, however, continue to scrutinise whether departmental verification genuinely establishes identity and culpability or merely recycles untested allegations. Magistrates must strike a balance: procedural safeguards exist to prevent harassment, but they cannot be allowed to become a backdoor to frustrate legitimate regulatory enforcement.

Conclusion

The judgment is a measured affirmation of the prosecutorial competence of statutory Inspectors and an admonition against premature judicial intervention on matters of limitation and territorial enquiry when procedural safeguards and corroborative material exist. The Supreme Court restored the prosecution while preserving the trial court’s role to adjudicate factual questions, particularly those touching corporate responsibility under Section 34 of the Drugs Act.

Extract from the Judgment

Limitation, Section 32 and Section 202 CrPC

From the aforesaid, it transpires that the initial complaint dated 05.01.2006 was made by one Mr. Joy Mandi and was received by the Drugs Inspector on 16.01.2006, alleging that although he had purchased two ampoules of Easy Five Pentavalent Vaccine for immunization of his child at the Primary Health Centre, as was represented on the outer packaging, but the vial inside had the label Tetravalent vaccine Easy Four.

On 21.01.2006, the Drugs Inspector inspected the premises of M/s Meenakshi Medical Agencies, Thrissur, Kerala from where the said drug had been purchased by Mr. Joy Mandi and found that the subject drug was not available and thus, original invoices towards purchase of the subject drugs by A-7 from A-5, carbon copies of invoices towards sale of subject drugs by A7 and credit note towards return of subject drug to A-5 by A-7 were seized. A-8 in his Statement on 21.01.2006 stated that some vials of the subject drugs were wrongly labelled and that the balance stock of the subject drug was returned to the supplier due to improper labelling (Misbranded). The Sales Representatives of A-7 (firm), Mr. Rajendran, on the same day, made a Statement that two vials of the subject drug were sold to Mr. Joy Mandi or CW-2 from A7 firm, and the balance stock of the subject drug was returned to the Supplier A5 due to improper labelling. He further stated that four vials of the subject drug were traced from the balance stock with labelling defects (misbranded). A-8 vide Statement recorded on 06.04.2006, submitted his explanation for the discrepancies in the sales record of the subject drug. A-8 affirmed that some of the vials of the subject drugs were found wrongly labelled and returned to the Supplier A5, and a credit note was obtained from them. Thereafter, as per request, the Drugs Inspector inspected the premises of A-5 (firm).

On 18.04.2006, certified copies of original invoices pertaining to the purchase of the subject drug from A-5 by A-7, certified copies of invoices pertaining to the sale of the subject drug from A-5 to A7 and certified copies of the credit note issued by A-5 to A-3 were taken along with other connected documents. On the same day i.e., 18.04.2006, the Drugs Inspector also inspected the premises of A-3 (firm) from where certified copies of purchase invoices pertaining to the subject drug by A-3 (firm) from A-1, certified copies of invoices pertaining to the sale of drugs by A-3 (firm) to A-5 and certified copies of credit notes pertaining to return of subject drugs from A-3 (firm) to A-1 were taken. The aforesaid certified copies of relevant details or documents obtained from A-3 (firm) to A-5 were then forwarded by the Drugs Inspector.

We are of the considered opinion that the State adopted the correct approach, by virtue of Section 32 of the Act. In the present case, the Complaint was made by a Gazetted Officer of the State of Kerala, who was authorised in this behalf viz. the Drugs Inspector (Intelligence Branch), Office of the Assistant Drugs Controller, Thrissur, Kerala. The chain that emerges is that the Competent Authority having received a complaint from a private party put in motion a verification or investigation process, which was completed within three months, only whereafter the exact identity of the accused was established. In our considered view, hence, the time for making a complaint to the Court would start ticking only therefrom.